Abivax

Equities

ABVX

FR0012333284

Biotechnology & Medical Research

Real-time Euronext Paris Other stock markets 03:09:53 2024-07-18 am EDT			5-day change	1st Jan Change
12.28 ^EUR	-0.65%		-2.07%	+25.05%

Jul. 16	Abivax: phase 3 data delayed to Q2 2025	CF
Jul. 15	Abivax SA Provides Updates on Ongoing Clinical Trials	CI

ABIVAX Société Anonyme Appoints Carol L. Brosgart, M.D. to its Board of Directors, Effective January 22, 2018

January 29, 2018 at 02:00 am EST

ABIVAX Société Anonyme announced the appointment as of January 22, 2018, of Dr. Carol L. Brosgart. He is a seasoned veteran with decades of infectious diseases experience, specifically in HIV clinical research and development.

Latest news about Abivax

Abivax: phase 3 data delayed to Q2 2025	Jul. 16	CF
Abivax SA Provides Updates on Ongoing Clinical Trials	Jul. 15	CI
Abivax SA Announces Management Changes	Jul. 15	CI
BTIG Initiates Abivax at Buy Rating With $43 Price Target	May. 20	MT
Abivax: four abstracts to be presented on obefazimod	May. 08	CF
Abivax SA Announces Presentation of Four Abstracts for Obefazimod in Ulcerative Colitis and Preclinical Colon Cancer Model At Digestive Disease Week 2024	May. 08	CI
Abivax: share price rises as two analysts express optimism	Apr. 29	CF
Piper Sandler Starts Abivax With Overweight Rating, $42 Price Target	Apr. 29	MT
Guggenheim Starts Abivax With Buy Rating, $50 Price Target	Apr. 29	MT
Morgan Stanley Adjusts Price Target on Abivax to $16 From $15, Maintains Equalweight Rating	Apr. 11	MT
Transcript : ABIVAX Société Anonyme, 2023 Earnings Call, Apr 08, 2024	Apr. 08
ABIVAX Société Anonyme Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 02	CI
Abivax: presentation on obefazimod at the ECCO congress	Feb. 13	CF
ABIVAX Société Anonyme Appoints Ana Sharma as Global Head of Quality	Feb. 07	CI
Abivax appoints new head of quality	Feb. 07	CF
Transcript : ABIVAX Société Anonyme - Special Call	Feb. 06
Abivax Modifies Trial Design of Phase 2b Development Program After US FDA Feedback	Feb. 02	MT
Abivax Announces Update to Obefazimod Phase 2B Clinical Development Program in Moderately to Severely Active Crohn?s Disease	Feb. 02	CI
Abivax to Host KOL Investor Event to Review Phase 2B Clinical Data and Phase 3 Trial Design for Obefazimod in Patients with Moderately to Severely Active Ulcerative Colitis	Jan. 24	CI
Abivax: share price rises after strategic update	Jan. 22	CF
Certain Warrants of ABIVAX Société Anonyme are subject to a Lock-Up Agreement Ending on 18-JAN-2024.	Jan. 17	CI
Certain Ordinary Shares of ABIVAX Société Anonyme are subject to a Lock-Up Agreement Ending on 18-JAN-2024.	Jan. 17	CI
Abivax: Sofinnova Partners falls below 10% of voting rights	23-10-30	CF
Abivax Raises $235.8 Million via Nasdaq IPO	23-10-24	MT
Abivax Closes Nasdaq IPO With $235.8 Million in Gross Proceeds	23-10-24	MT

Chart Abivax

Duration

Period

More charts

Company Profile

Abivax develops innovative treatments modulating the body's natural immune system machinery to treat patients with chronic inflammatory diseases, viral infections and cancer. As a clinical-stage company, Abivax leverages its immune enhancing and antiviral platforms to optimize and develop drug candidates to treat ulcerative colitis, Crohn's disease, rheumatoid arthritis, and other inflammatory diseases (ABX464) as well as liver cancer (ABX196). The Company's mission is to utilize its drug development platforms to bring innovative and effective solutions to patients in these therapeutic areas with significant unmet needs.

Sector

Biotechnology & Medical Research

Calendar

2024-09-08 - Q2 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Abivax

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

12.36 EUR

Average target price

36.34 EUR

Spread / Average Target

+194.01%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
ABIVAX	+25.05%	850M
MODERNA, INC.	+24.74%	47.54B
IQVIA HOLDINGS INC.	-0.47%	41.96B
LONZA GROUP AG	+44.36%	41.55B
ALNYLAM PHARMACEUTICALS, INC.	+25.40%	30.36B
ICON PUBLIC LIMITED COMPANY	+17.96%	27.61B
CELLTRION, INC.	-4.47%	28.7B
UNITED THERAPEUTICS CORPORATION	+50.73%	14.7B
MEDPACE HOLDINGS, INC.	+42.56%	13.51B
BIO-TECHNE CORPORATION	+1.46%	12.34B

Other Biotechnology & Medical Research